This article (1) has been retracted at the request of the editors. Internal review detected instances of image reuse. Specifically, the Nanog immunofluorescent image in Fig. 6B is duplicated in PBS-treated/control shRNA-expressing and cisplatin-treated/Rac1 shRNA-expressing conditions.
A copy of this Retraction Notice was sent to the last known email addresses for all six authors. Four authors (Seo-Jeong Cho, Kevin K. Chang, Sandra W. Ryeom, and Sam S. Yoon) agreed to the retraction; two authors (Changhwan Yoon and Do Joong Park) did not respond.
NOTE—Additional information for the reader follows.
Figures in this article (1) appear to be published in later articles. Specifically, there appear to be image duplications between Supplementary Fig. 1C of this article and Supplementary Fig. S5B of a subsequent article that has been retracted (2). There also appears to be a duplication in Fig. 2D of this article and Fig. 2B of a subsequent article that has been retracted (3). Internal review also indicates an apparent duplication in Supplementary Fig. 1C of this article and Fig. 1H of a subsequent article that has since been retracted (4). Finally, Fig. 6A of this article appears to be duplicated in Fig. 4 in a subsequent article in an unrelated journal (5).
Footnotes
References
- 1.Yoon C, Cho S-J, Chang KK, Park DJ, Ryeom S, Yoon SS. Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res 2017;15:1106–16. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 2.Yoon C, Till J, Cho S-J, Chang KK, Lin J-X, Huang C-M, et al. RETRACTED: KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem–like cells and promotes metastasis. Mol Cancer Res 2019;17:1945–57. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 3.Lu J, Bang H, Kim SM, Cho S-J, Ashktorab H, Smoot DT, et al. RETRACTED ARTICLE: Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling. Oncogene 2021;40:922–36. [DOI] [PubMed] [Google Scholar]
- 4.Huang C, Yoon C, Zhou XH, Zhou Y-C, Zhou W-W, Liu H, et al. RETRACTED ARTICLE: ERK1/2-Nanog signaling pathway enhances CD44(+) cancer stem-like cell phenotypes and epithelial-to-mesenchymal transition in head and neck squamous cell carcinomas. Cell Death Dis 2020;11:266. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 5.Yoon C, Lu J, Yi BC, Chang KK, Simon MC, Ryeom S, et al. PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas. Oncogenesis 2021;10:12. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]